BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
Rhea-AI Summary
BioCardia (NASDAQ:BCDA) will host a conference call on Wednesday, August 12, 2026 at 4:30 PM EDT to provide a corporate update and report its Q2 2026 financial results. The event will include prepared remarks followed by a question-and-answer session.
Participants can register online to receive dial-in details or join by phone at 1-833-316-0559 (U.S.) or 1-412-317-5730 (international). A live webcast and both webcast and telephonic replays will be available, with webcast replay access through approximately November 12, 2026.
Positive
- None.
Negative
- None.
Key Figures
Previous Conferences,earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 11 | Q1 call scheduled | Neutral | +0.9% | Q1 2026 results and corporate update call scheduled for May 15 |
| Mar 19 | Annual call scheduled | Neutral | +0.0% | 2025 financial results and corporate update call scheduled for March 24 |
| Nov 05 | Q3 call scheduled | Neutral | -3.0% | Q3 2025 corporate update and financial results call scheduled for November 12 |
| Aug 06 | Q2 call scheduled | Neutral | -5.5% | Q2 2025 corporate update and financial results call scheduled for August 11 |
| May 09 | Q1 call scheduled | Neutral | -0.3% | Q1 2025 corporate update and financial results call scheduled for May 14 |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific history showed mixed reactions, including a -5.52% move and a 0% move; the average move was -1.6%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the second quarter of 2026 by conference call on Wednesday, August 12, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session.
Participants can register for the conference by navigating to: https://dpregister.com/sreg/10211154/104a4f51d2e.
Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=ufQzaenK.
A webcast replay of the call will be available approximately one hour after the end of the call through approximately November 12, 2026 at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will also be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada), 1-412-317-0088 (international toll) by using access code 3063624.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart 3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biological therapies. For more information visit www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
